Registered title, quoted from ClinicalTrials.gov
DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Renji Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06353126, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 3
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (3 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
ECOG-PS score 0-1;
Inclusion criterion 6
Renal dysfunction, creatinine >176.8 umol/L or creatinine clearance rate <30ml/min;
Exclusion criterion 10
White blood cell count <3.0x109/L, platelet count <50x106/L, and unable to correct;
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06353126, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18-75 years;
- Subjects with viral hepatitis or cirrhosis are clinically diagnosed according to AASLD standards, which require a history of viral hepatitis or cirrhosis combined with imaging examinations (enhanced CT, MRI, second-generation ultrasound contrast agents). When the tumor diameter is greater than 2 cm, a diagnosis can be made if one imaging technique shows typical arterial phase rapid enhancement and rapid washout. If the diameter is 1-2 cm, two imaging techniques must confirm this, or one imaging technique confirms it and alpha-fetoprotein (AFP) is greater than 400 ng/ml. For subjects who cannot be clinically diagnosed, histological or cytological biopsy confirmation is required; original biopsy records can also be used for diagnosis.
- Child-Pugh score A-B grade;
- Tumor present in the right lobe of the liver;
- Liver cancer assessment meeting the "up to seven" criteria: the sum of tumor size and number does not exceed 7;
- ECOG-PS score 0-1;
- Scheduled for living donor liver transplantation as the primary treatment;
- Signed informed consent form.
Exclusion Criteria:
- Presence of definite cancer thrombi in the main portal vein, vena cava, or main bile duct;
- Severe hepatic encephalopathy;
- Coexisting pulmonary arterial hypertension (moderate to high risk, WHO Grade III-IV);
- Severe contrast agent allergy;
- Irreversible hepatic artery to hepatic vein shunt;
- Special types of anatomical variations (Asan portal vein type III);
- Extrahepatic metastatic tumors;
- Concurrent active hepatitis or severe infection;
- Tumor dissemination or distant metastasis, expected survival <3 months;
- Renal dysfunction, creatinine >176.8 umol/L or creatinine clearance rate <30ml/min;
- White blood cell count <3.0x109/L, platelet count <50x106/L, and unable to correct;
- Inability to tolerate surgical anesthesia (severe infection, cardiopulmonary insufficiency, cerebrovascular disease);
- Severe psychiatric illness;
- Other reasons deemed unsuitable for participation by the investigator.
Quoted from ClinicalTrials.gov, NCT06353126, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06353126, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.